536 related articles for article (PubMed ID: 36284349)
1. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
2. B7-H3/CD276: An Emerging Cancer Immunotherapy.
Zhou WT; Jin WL
Front Immunol; 2021; 12():701006. PubMed ID: 34349762
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
5. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
Yang S; Wei W; Zhao Q
Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
[TBL] [Abstract][Full Text] [Related]
6. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
[TBL] [Abstract][Full Text] [Related]
7. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
8. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
[TBL] [Abstract][Full Text] [Related]
9. B7-H3-mediated tumor immunology: Friend or foe?
Wang L; Kang FB; Shan BE
Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
[TBL] [Abstract][Full Text] [Related]
10. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention.
Varghese E; Samuel SM; Brockmueller A; Shakibaei M; Kubatka P; Büsselberg D
Cancer Metastasis Rev; 2024 Mar; 43(1):115-133. PubMed ID: 37768439
[TBL] [Abstract][Full Text] [Related]
12. A promising target for breast cancer: B7-H3.
Jiang Y; Liu J; Chen L; Qian Z; Zhang Y
BMC Cancer; 2024 Feb; 24(1):182. PubMed ID: 38326735
[TBL] [Abstract][Full Text] [Related]
13. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
14. The role of B7-H3 in tumors and its potential in clinical application.
Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
[TBL] [Abstract][Full Text] [Related]
15. B7-H3 Immune Checkpoint Protein in Human Cancer.
Flem-Karlsen K; Fodstad Ø; Nunes-Xavier CE
Curr Med Chem; 2020; 27(24):4062-4086. PubMed ID: 31099317
[TBL] [Abstract][Full Text] [Related]
16. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients.
Maeda N; Yoshimura K; Yamamoto S; Kuramasu A; Inoue M; Suzuki N; Watanabe Y; Maeda Y; Kamei R; Tsunedomi R; Shindo Y; Inui M; Tamada K; Yoshino S; Hazama S; Oka M
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(Suppl 4):S546-54. PubMed ID: 24562936
[TBL] [Abstract][Full Text] [Related]
17. B7-H3 role in the immune landscape of cancer.
Castellanos JR; Purvis IJ; Labak CM; Guda MR; Tsung AJ; Velpula KK; Asuthkar S
Am J Clin Exp Immunol; 2017; 6(4):66-75. PubMed ID: 28695059
[TBL] [Abstract][Full Text] [Related]
18. Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.
Khan M; Arooj S; Wang H
Front Immunol; 2021; 12():651634. PubMed ID: 34531847
[TBL] [Abstract][Full Text] [Related]
19. New checkpoints in cancer immunotherapy.
Ni L; Dong C
Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
[TBL] [Abstract][Full Text] [Related]
20. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
Pizon M; Schott DS; Pachmann U; Pachmann K
Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
